A new Phase 3 clinical trial testing Kyverna Therapeutics’ cell therapy candidate KYV-101 in people with myasthenia gravis (MG) — a study the developer says “supports [a] clear and rapid path […] The post ‘FDA-aligned’ trial of KYV-101 for MG likely to start enrolling this year appeared first on Myasthenia Gravis News.| Myasthenia Gravis News – The Web's Daily Resource for Myasthenia Gravis News
An open-label, multicenter Phase 2 clinical trial will test KYV-101 in people with refractory MG and positive for self-reactive antibodies.| Myasthenia Gravis News